These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 28353224)

  • 1. What Have Proteomic Studies Taught Us About Novel Drug Targets in Autism?
    Guest PC; Martins-de-Souza D
    Adv Exp Med Biol; 2017; 974():49-67. PubMed ID: 28353224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The need for a comprehensive molecular characterization of autism spectrum disorders.
    Broek JA; Brombacher E; Stelzhammer V; Guest PC; Rahmoune H; Bahn S
    Int J Neuropsychopharmacol; 2014 Apr; 17(4):651-73. PubMed ID: 24229490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synapse dysfunction in autism: a molecular medicine approach to drug discovery in neurodevelopmental disorders.
    Spooren W; Lindemann L; Ghosh A; Santarelli L
    Trends Pharmacol Sci; 2012 Dec; 33(12):669-84. PubMed ID: 23084458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenomic medicine in autism: challenges and opportunities.
    Bowers K; Lin PI; Erickson C
    Paediatr Drugs; 2015 Apr; 17(2):115-24. PubMed ID: 25420674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarkers in autism spectrum disorder: the old and the new.
    Ruggeri B; Sarkans U; Schumann G; Persico AM
    Psychopharmacology (Berl); 2014 Mar; 231(6):1201-16. PubMed ID: 24096533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Developing new pharmacotherapies for autism.
    Ecker C; Spooren W; Murphy D
    J Intern Med; 2013 Oct; 274(4):308-20. PubMed ID: 23865950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteomics and Metabolomics Approaches towards a Functional Insight onto AUTISM Spectrum Disorders: Phenotype Stratification and Biomarker Discovery.
    Ristori MV; Mortera SL; Marzano V; Guerrera S; Vernocchi P; Ianiro G; Gardini S; Torre G; Valeri G; Vicari S; Gasbarrini A; Putignani L
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32872562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential benefits and limits of psychopharmacological therapies in pervasive developmental disorders.
    Molteni M; Nobile M; Cattaneo D; Radice S; Clementi E
    Curr Clin Pharmacol; 2014; 9(4):365-76. PubMed ID: 24050744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pilot proteomic study of protein markers in autism spectrum disorder.
    Ngounou Wetie AG; Wormwood K; Thome J; Dudley E; Taurines R; Gerlach M; Woods AG; Darie CC
    Electrophoresis; 2014 Jul; 35(14):2046-54. PubMed ID: 24687421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mass spectrometry for the study of autism and neurodevelopmental disorders.
    Ngounou Wetie AG; Dekroon RM; Mocanu M; Ryan JP; Darie CC; Woods AG
    Adv Exp Med Biol; 2014; 806():525-44. PubMed ID: 24952201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Profiling for novel proteomics biomarkers in neurodevelopmental disorders.
    Dudley E; Hässler F; Thome J
    Expert Rev Proteomics; 2011 Feb; 8(1):127-36. PubMed ID: 21329432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subphenotype-dependent disease markers for diagnosis and personalized treatment of autism spectrum disorders.
    Hu VW
    Dis Markers; 2012; 33(5):277-88. PubMed ID: 22960334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autism spectrum disorder: an omics perspective.
    Woods AG; Wormwood KL; Wetie AG; Aslebagh R; Crimmins BS; Holsen TM; Darie CC
    Proteomics Clin Appl; 2015 Feb; 9(1-2):159-68. PubMed ID: 25311756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Higher-functioning pervasive developmental disorders: rates and patterns of psychotropic drug use.
    Martin A; Scahill L; Klin A; Volkmar FR
    J Am Acad Child Adolesc Psychiatry; 1999 Jul; 38(7):923-31. PubMed ID: 10405512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Pilot Proteomic Analysis of Salivary Biomarkers in Autism Spectrum Disorder.
    Ngounou Wetie AG; Wormwood KL; Russell S; Ryan JP; Darie CC; Woods AG
    Autism Res; 2015 Jun; 8(3):338-50. PubMed ID: 25626423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autism: cause factors, early diagnosis and therapies.
    Bhat S; Acharya UR; Adeli H; Bairy GM; Adeli A
    Rev Neurosci; 2014; 25(6):841-50. PubMed ID: 25222596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of autism spectrum disorders--autism and developmental disabilities monitoring network, six sites, United States, 2000.
    ;
    MMWR Surveill Summ; 2007 Feb; 56(1):1-11. PubMed ID: 17287714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug discovery for autism spectrum disorder: challenges and opportunities.
    Ghosh A; Michalon A; Lindemann L; Fontoura P; Santarelli L
    Nat Rev Drug Discov; 2013 Oct; 12(10):777-90. PubMed ID: 24080699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psychopharmacological treatment in children and adolescents with autism spectrum disorders in Germany.
    Bachmann CJ; Manthey T; Kamp-Becker I; Glaeske G; Hoffmann F
    Res Dev Disabil; 2013 Sep; 34(9):2551-63. PubMed ID: 23747941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Connecting Brain Proteomics with Behavioural Neuroscience in Translational Animal Models of Neuropsychiatric Disorders.
    Sarnyai Z; Guest PC
    Adv Exp Med Biol; 2017; 974():97-114. PubMed ID: 28353227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.